Latigo Biotherapeutics, Inc. Common Stock (LTGO) - Net Assets
Based on the latest financial reports, Latigo Biotherapeutics, Inc. Common Stock (LTGO) has net assets worth $-252.58 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($50.58 Million) and total liabilities ($303.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see LTGO market cap.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-252.58 Million |
| % of Total Assets | -499.36% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Latigo Biotherapeutics, Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Latigo Biotherapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data.
Annual Net Assets for Latigo Biotherapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Latigo Biotherapeutics, Inc. Common Stock from 2024 to 2025. See LTGO net asset quality score to measure how much of total assets are equity-financed.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-231.67 Million | -78.76% |
| 2024-12-31 | $-129.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Latigo Biotherapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10916700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $11.46 Million | % |
| Total Equity | $-231.67 Million | 100.00% |
Latigo Biotherapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Latigo Biotherapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Leshan Giantstar Farming & Husbandry Corp Ltd
SHG:603477
|
$1.10 Billion |
|
Sichuan Haite High-tech Co Ltd
SHE:002023
|
$1.10 Billion |
|
ZYNP Corp
SHE:002448
|
$1.10 Billion |
|
Xinjiang Communications Construction Group Co Ltd Class A
SHE:002941
|
$1.10 Billion |
|
BioPharma Credit PLC
LSE:BPCR
|
$1.10 Billion |
|
Goldman Sachs BDC Inc
NYSE:GSBD
|
$1.10 Billion |
|
Sitronix Technology Corp
TW:8016
|
$1.10 Billion |
|
Prospect Capital Corporation
NASDAQ:PSEC
|
$1.10 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Latigo Biotherapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -129,599,000 to -231,674,000, a change of -102,075,000.
- Net loss of 109,167,000 reduced equity.
- New share issuances of 149,379,000 increased equity.
- Other factors decreased equity by 142,287,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-109.17 Million | -47.12% |
| Share Issuances | $149.38 Million | +64.48% |
| Other Changes | $-142.29 Million | -61.42% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Latigo Biotherapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Latigo Biotherapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-48.22 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-86.00 Million |
Industry Comparison
This section compares Latigo Biotherapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $49,343,171
- Average return on equity (ROE) among peers: -63.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Latigo Biotherapeutics, Inc. Common Stock (LTGO) | $-252.58 Million | 0.00% | N/A | $1.10 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $148.49 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.59 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $-2.99 Million | 0.00% | 0.00x | $23.14 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $10.02 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $12.11 Million | -372.67% | 3.10x | $5.07 Billion |
About Latigo Biotherapeutics, Inc. Common Stock
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting … Read more